“Satellite V” began to be used as drops for the nose. Experts claim that additional tests are needed

In August, in August, they began to use a vaccine for nasal vaccination against coronavirus for intramuscular injections "Sputnik V", Russian Forbes writes . However, experts doubt the effectiveness of this method. The head of the scientific examination of the pharmaceutical venture fund Inbio Ventures, Ilya Yasny, in a conversation with The Insider confirmed that this method of introducing a vaccine must be examined separately, since unwanted side effects are possible.

Forbes noticed that on August 26, the registered nasal form of the "satellite" was never released into circulation. The publication came to the conclusion that in the Kursk region it is precisely the injection vaccine. In the Ministry of Health, reporters confirmed that in a solution for intramuscular injection and in the nasal drops "the composition of the drug is absolutely identical." At the same time, the instructions for the use of the "satellite" say that "intranasal introduction of the vaccine is allowed using a dosing device" was assured in the department.

“The drug can be used in the way that is indicated in the instructions for its medical use, so legally no contradictions arise here.”

The top manager of one of the large pharmaceutical distributors said that the solution contained in injection bottles and for nasal use can indeed be the same. However, he recalled that de jure is still another drug that has another registration certificate. This means that it can be used "only in accordance with this registration certificate."

Director of the Institute of Interdisciplinary Medical Research Institute of the European University in St. Petersburg, Anton Barchuk told the publication that it is possible to answer all questions about the effectiveness and safety of the nasal vaccine in three words: “We do not know!” According to him, any new drug requires individual clinical studies, no results were published according to the intranasal vaccine. Barkchuk said that the Satellite V intramuscular vaccine passed the necessary phases of clinical studies and additional studies.

“You can hope that other derivatives will be also effective, but these are only assumptions, hypotheses that need to be checked properly, and during the pandemic one of the errors there was a launch and introduction of some vaccines until clinical studies are completed.”

The head of the scientific examination of the pharmaceutical venture fund Inbio Ventures, Ilya Yasny, in a conversation with The Insider completely agreed with the Barkchuk’s opinion that each method of introducing a vaccine should be examined separately.

“They hope that the nasal vaccine will be more effective in preventing, because it will cause the formation of local immune protection in the mucous membranes of the upper respiratory tract, but this requires evidence. So far, no effective nasal vaccine has been registered in the world, although many have tried. From coronavirus (such a vaccine) is still in development. There are fears that local immunity will not be formed, and systemic also, because it is not an injection. Unwanted phenomena are also possible. ”

In January of this year, Ginzburg announced the beginning of clinical tests of the nasal vaccine, to which the government allocated 187.8 million rubles, quoted it Interfax. It was not reported that the drug would be completely identical to the "satellite V". Then Ginzburg claimed that Omicron is transmitted “with terrible force”, so people need a nasal vaccine: “If we had it now, we would spray nasal form in our nose so that they were not infected.”

The molecular biologist and scientific journalist Irina Yakutenko previously told The Insider that Omicron has changed a lot compared to its predecessors and are no longer able to prevent its penetration into cells after vaccination. Both vaccinated and illuminated can become infected again. The biologist called the problem of the problem of changing vaccines in order for them to stimulate the production of antibodies that learn new varieties of SARS-COV-2. She noted that the manufacturers of the PFIZER/BIONTECH and Moderna MRNC-Vaccines, as well as the creators of the Russian “satellite” have developed new versions of vaccines modified under the Omicron.